Luna PC, Chu CY, Fatani M, et al. Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis. Dermatol Ther (Heidelb). 2023;13(12):3043–55.

Article  PubMed  Google Scholar 

AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis-comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–71.

Article  PubMed  Google Scholar 

Belinchón Romero I, Dauden E, Ferrándiz Foraster C, González-Cantero Á, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med. 2021;53(1):1727–36.

Article  PubMed  PubMed Central  Google Scholar 

Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.

Article  PubMed  Google Scholar 

Manalo IF, Gilbert KE, Wu JJ. An updated survey for the 2007–2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. J Eur Acad Dermatol Venereol. 2015;29(10):1945–50.

Article  CAS  PubMed  Google Scholar 

Leonardi C, See K, Gallo G, et al. Psoriasis severity assessment combining physician and patient reported outcomes: the optimal psoriasis assessment tool. Dermatol Ther (Heidelb). 2021;11(4):1249–63.

Article  PubMed  Google Scholar 

Augustin M, Sommer R, Daudén E, et al. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study). BMJ Open. 2023;13(2):e060536.

Article  PubMed  PubMed Central  Google Scholar 

Feldman SR, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65–8.

Article  PubMed  PubMed Central  Google Scholar 

Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369–75.

Article  PubMed  Google Scholar 

Spuls PI, Lecluse LLA, Poulsen MLNF, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–43.

Article  CAS  PubMed  Google Scholar 

Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):17–22.

Article  PubMed  Google Scholar 

Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.

CAS  PubMed  Google Scholar 

Pinter A, van de Kerkhof P. The role of topical therapies along the psoriasis patient journey: an overview from the Symposium “Tailoring topical psoriasis treatments to patients” needs and expectations’ of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):3–8.

Article  CAS  PubMed  Google Scholar 

Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599–620.

Article  CAS  PubMed  Google Scholar 

Torres T, Galván J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther (Heidelb). 2023;13(10):2153–69.

Article  PubMed  Google Scholar 

García N, Guiró P, Galván J, et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:1–8.

Article  Google Scholar 

Pinter A, Reich A, Arenberger P, et al. Randomized phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37(11):2327–35.

Article  CAS  PubMed  Google Scholar 

Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–5.

Article  PubMed  Google Scholar 

López Estebaranz JL, Kurzen H, Galván J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatolog Treat. 2024;35(1):2357618.

Article  PubMed  Google Scholar 

Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228–36.

Article  CAS  PubMed  Google Scholar 

Baracaldo-Santamaría D, Feliciano-Alfonso JE, Ramirez-Grueso R, Rojas-Rodríguez LC, Dominguez-Dominguez CA, Calderon-Ospina CA. Making sense of composite endpoints in clinical research. JCM. 2023;12(13):4371.

Article  PubMed  PubMed Central  Google Scholar 

Walsh JA, Jones H, Mallbris L, et al. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2018;8:65–74.

PubMed  Google Scholar 

Gold LS, Hansen JB, Patel D, Veverka KA, Strober B. PGAxBSA composite versus PASI: comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. J Am Acad Dermatol. 2020;83(1):131–8.

Article  CAS  PubMed  Google Scholar 

Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594–6.

Article  PubMed  PubMed Central  Google Scholar 

Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158–66.

Article  CAS  PubMed  Google Scholar 

Carretero G, Puig L, Carrascosa JM, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334–46.

Article  CAS  PubMed  Google Scholar 

Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13–7.

Article  PubMed  Google Scholar 

Enríquez-Navascués JM, Aguirre-Allende I. Concept of risk factor as an estimate of association and treatment effect: measures and meaning. Cir Esp (Engl Ed). 2022;100(10):652–5.

Article  PubMed  Google Scholar 

González-Domínguez A, García-Agua N, Dauden E, Ventayol-Bosch P. The utility of long-term number needed to treat to evaluate interleukin 17 and 23 inhibitor therapies in the treatment of moderate to severe plaque psoriasis. Actas Dermosifiliogr. 2024;115(4):427–9.

Article  Google Scholar 

Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–69.

Article  PubMed  PubMed Central  Google Scholar 

Ravasio R, Costanzo A, Antonelli S, Maiorino A, Losi S. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Glob Reg Health Technol Assess. 2021;8:53–7.

PubMed  PubMed Central